nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—Blood pressure systolic increased—Travoprost—glaucoma	0.0276	0.0865	CcSEcCtD
Ruxolitinib—GRK7—eye—glaucoma	0.0122	0.0903	CbGeAlD
Ruxolitinib—GRK7—retina—glaucoma	0.0121	0.0895	CbGeAlD
Ruxolitinib—Haemorrhage intracranial—Pilocarpine—glaucoma	0.00927	0.029	CcSEcCtD
Ruxolitinib—GRK1—eye—glaucoma	0.00884	0.0653	CbGeAlD
Ruxolitinib—GRK1—retina—glaucoma	0.00876	0.0647	CbGeAlD
Ruxolitinib—CAMK1D—eye—glaucoma	0.00519	0.0384	CbGeAlD
Ruxolitinib—JAK3—connective tissue—glaucoma	0.00516	0.0381	CbGeAlD
Ruxolitinib—CAMK1D—retina—glaucoma	0.00515	0.038	CbGeAlD
Ruxolitinib—JAK1—connective tissue—glaucoma	0.00513	0.0379	CbGeAlD
Ruxolitinib—Hypercholesterolaemia—Bimatoprost—glaucoma	0.00503	0.0158	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Carbachol—glaucoma	0.00488	0.0153	CcSEcCtD
Ruxolitinib—HIPK2—connective tissue—glaucoma	0.00479	0.0354	CbGeAlD
Ruxolitinib—ROCK1—eye—glaucoma	0.00458	0.0339	CbGeAlD
Ruxolitinib—ROCK1—retina—glaucoma	0.00454	0.0335	CbGeAlD
Ruxolitinib—Hypercholesterolaemia—Brimonidine—glaucoma	0.00446	0.014	CcSEcCtD
Ruxolitinib—ROCK1—connective tissue—glaucoma	0.00442	0.0326	CbGeAlD
Ruxolitinib—BMPR2—connective tissue—glaucoma	0.00429	0.0317	CbGeAlD
Ruxolitinib—Hypercholesterolaemia—Travoprost—glaucoma	0.00424	0.0133	CcSEcCtD
Ruxolitinib—Epistaxis—Metipranolol—glaucoma	0.00399	0.0125	CcSEcCtD
Ruxolitinib—CAMK2G—eye—glaucoma	0.00398	0.0294	CbGeAlD
Ruxolitinib—Weight decreased—Diclofenamide—glaucoma	0.00391	0.0122	CcSEcCtD
Ruxolitinib—BMP2K—connective tissue—glaucoma	0.00384	0.0284	CbGeAlD
Ruxolitinib—Pancytopenia—Methazolamide—glaucoma	0.00378	0.0118	CcSEcCtD
Ruxolitinib—MAP3K7—retina—glaucoma	0.00355	0.0262	CbGeAlD
Ruxolitinib—TYK2—eye—glaucoma	0.00352	0.026	CbGeAlD
Ruxolitinib—TYK2—retina—glaucoma	0.00349	0.0258	CbGeAlD
Ruxolitinib—MAP3K2—connective tissue—glaucoma	0.00349	0.0257	CbGeAlD
Ruxolitinib—MKNK2—eye—glaucoma	0.00347	0.0257	CbGeAlD
Ruxolitinib—MKNK2—retina—glaucoma	0.00344	0.0254	CbGeAlD
Ruxolitinib—TYK2—connective tissue—glaucoma	0.00339	0.025	CbGeAlD
Ruxolitinib—Haematuria—Methazolamide—glaucoma	0.00338	0.0106	CcSEcCtD
Ruxolitinib—MKNK2—connective tissue—glaucoma	0.00335	0.0247	CbGeAlD
Ruxolitinib—Urinary tract infection—Latanoprost—glaucoma	0.00334	0.0105	CcSEcCtD
Ruxolitinib—RET—connective tissue—glaucoma	0.00326	0.0241	CbGeAlD
Ruxolitinib—JAK2—connective tissue—glaucoma	0.00308	0.0228	CbGeAlD
Ruxolitinib—Flatulence—Carbachol—glaucoma	0.0029	0.00907	CcSEcCtD
Ruxolitinib—TAOK3—eye—glaucoma	0.00281	0.0208	CbGeAlD
Ruxolitinib—Hypercholesterolaemia—Betaxolol—glaucoma	0.0028	0.00876	CcSEcCtD
Ruxolitinib—TAOK3—retina—glaucoma	0.00279	0.0206	CbGeAlD
Ruxolitinib—Infestation NOS—Apraclonidine—glaucoma	0.00275	0.0086	CcSEcCtD
Ruxolitinib—Infestation—Apraclonidine—glaucoma	0.00275	0.0086	CcSEcCtD
Ruxolitinib—TAOK3—connective tissue—glaucoma	0.00271	0.02	CbGeAlD
Ruxolitinib—Haemorrhage—Apraclonidine—glaucoma	0.00247	0.00772	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Diclofenamide—glaucoma	0.00241	0.00754	CcSEcCtD
Ruxolitinib—Infection—Carbachol—glaucoma	0.00238	0.00747	CcSEcCtD
Ruxolitinib—Haematuria—Acetazolamide—glaucoma	0.00234	0.00734	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Acetazolamide—glaucoma	0.00232	0.00728	CcSEcCtD
Ruxolitinib—Weight decreased—Dorzolamide—glaucoma	0.00228	0.00716	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Latanoprost—glaucoma	0.00227	0.00711	CcSEcCtD
Ruxolitinib—Infestation—Travoprost—glaucoma	0.00224	0.00702	CcSEcCtD
Ruxolitinib—Infestation NOS—Travoprost—glaucoma	0.00224	0.00702	CcSEcCtD
Ruxolitinib—Infestation—Brinzolamide—glaucoma	0.00221	0.00693	CcSEcCtD
Ruxolitinib—Infestation NOS—Brinzolamide—glaucoma	0.00221	0.00693	CcSEcCtD
Ruxolitinib—Urinary tract infection—Dorzolamide—glaucoma	0.00219	0.00685	CcSEcCtD
Ruxolitinib—Urinary tract infection—Travoprost—glaucoma	0.00218	0.00683	CcSEcCtD
Ruxolitinib—Nervous system disorder—Latanoprost—glaucoma	0.00215	0.00673	CcSEcCtD
Ruxolitinib—Skin disorder—Latanoprost—glaucoma	0.00213	0.00667	CcSEcCtD
Ruxolitinib—Epistaxis—Dorzolamide—glaucoma	0.00212	0.00665	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Diclofenamide—glaucoma	0.00212	0.00665	CcSEcCtD
Ruxolitinib—Fatigue—Diclofenamide—glaucoma	0.00212	0.00664	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Brinzolamide—glaucoma	0.00209	0.00656	CcSEcCtD
Ruxolitinib—Epistaxis—Brinzolamide—glaucoma	0.00209	0.00654	CcSEcCtD
Ruxolitinib—Urinary tract infection—Pilocarpine—glaucoma	0.00207	0.00648	CcSEcCtD
Ruxolitinib—Haematuria—Pilocarpine—glaucoma	0.00203	0.00635	CcSEcCtD
Ruxolitinib—Epistaxis—Pilocarpine—glaucoma	0.00201	0.00629	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Methazolamide—glaucoma	0.00195	0.00612	CcSEcCtD
Ruxolitinib—Fatigue—Methazolamide—glaucoma	0.00195	0.00611	CcSEcCtD
Ruxolitinib—Body temperature increased—Diclofenamide—glaucoma	0.00194	0.00609	CcSEcCtD
Ruxolitinib—Asthenia—Metipranolol—glaucoma	0.00194	0.00606	CcSEcCtD
Ruxolitinib—Body temperature increased—Carbachol—glaucoma	0.0019	0.00594	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Apraclonidine—glaucoma	0.00181	0.00568	CcSEcCtD
Ruxolitinib—Asthenia—Carteolol—glaucoma	0.00179	0.00562	CcSEcCtD
Ruxolitinib—Body temperature increased—Methazolamide—glaucoma	0.00179	0.0056	CcSEcCtD
Ruxolitinib—Dizziness—Metipranolol—glaucoma	0.00178	0.00559	CcSEcCtD
Ruxolitinib—Asthenia—Diclofenamide—glaucoma	0.00176	0.00552	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Bimatoprost—glaucoma	0.00176	0.00551	CcSEcCtD
Ruxolitinib—Infection—Apraclonidine—glaucoma	0.00174	0.00545	CcSEcCtD
Ruxolitinib—Pruritus—Diclofenamide—glaucoma	0.00174	0.00545	CcSEcCtD
Ruxolitinib—Weight increased—Clonidine—glaucoma	0.00173	0.00543	CcSEcCtD
Ruxolitinib—Malnutrition—Brinzolamide—glaucoma	0.00173	0.00542	CcSEcCtD
Ruxolitinib—Nervous system disorder—Apraclonidine—glaucoma	0.00172	0.00538	CcSEcCtD
Ruxolitinib—Flatulence—Brinzolamide—glaucoma	0.0017	0.00534	CcSEcCtD
Ruxolitinib—Skin disorder—Apraclonidine—glaucoma	0.0017	0.00533	CcSEcCtD
Ruxolitinib—Asthenia—Levobunolol—glaucoma	0.0017	0.00531	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Betaxolol—glaucoma	0.00169	0.0053	CcSEcCtD
Ruxolitinib—Headache—Metipranolol—glaucoma	0.00169	0.0053	CcSEcCtD
Ruxolitinib—Infection—Bimatoprost—glaucoma	0.00169	0.00528	CcSEcCtD
Ruxolitinib—Pruritus—Levobunolol—glaucoma	0.00167	0.00524	CcSEcCtD
Ruxolitinib—Nervous system disorder—Bimatoprost—glaucoma	0.00167	0.00522	CcSEcCtD
Ruxolitinib—Dizziness—Carteolol—glaucoma	0.00165	0.00518	CcSEcCtD
Ruxolitinib—Urinary tract infection—Clonidine—glaucoma	0.00165	0.00517	CcSEcCtD
Ruxolitinib—Skin disorder—Bimatoprost—glaucoma	0.00165	0.00517	CcSEcCtD
Ruxolitinib—Flatulence—Pilocarpine—glaucoma	0.00164	0.00513	CcSEcCtD
Ruxolitinib—Dizziness—Diclofenamide—glaucoma	0.00163	0.00509	CcSEcCtD
Ruxolitinib—Asthenia—Methazolamide—glaucoma	0.00162	0.00509	CcSEcCtD
Ruxolitinib—Epistaxis—Clonidine—glaucoma	0.0016	0.00502	CcSEcCtD
Ruxolitinib—Dizziness—Carbachol—glaucoma	0.00159	0.00497	CcSEcCtD
Ruxolitinib—Headache—Carteolol—glaucoma	0.00157	0.00491	CcSEcCtD
Ruxolitinib—Dizziness—Levobunolol—glaucoma	0.00156	0.00489	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Brimonidine—glaucoma	0.00156	0.00488	CcSEcCtD
Ruxolitinib—Pruritus—Latanoprost—glaucoma	0.00155	0.00485	CcSEcCtD
Ruxolitinib—Headache—Diclofenamide—glaucoma	0.00154	0.00482	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Acetazolamide—glaucoma	0.00153	0.0048	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Apraclonidine—glaucoma	0.00151	0.00474	CcSEcCtD
Ruxolitinib—Fatigue—Apraclonidine—glaucoma	0.00151	0.00473	CcSEcCtD
Ruxolitinib—Weight increased—Betaxolol—glaucoma	0.00151	0.00473	CcSEcCtD
Ruxolitinib—Headache—Carbachol—glaucoma	0.0015	0.00471	CcSEcCtD
Ruxolitinib—Weight decreased—Betaxolol—glaucoma	0.0015	0.0047	CcSEcCtD
Ruxolitinib—Infection—Brimonidine—glaucoma	0.00149	0.00468	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Travoprost—glaucoma	0.00148	0.00464	CcSEcCtD
Ruxolitinib—Headache—Levobunolol—glaucoma	0.00148	0.00464	CcSEcCtD
Ruxolitinib—Infestation—Betaxolol—glaucoma	0.00148	0.00463	CcSEcCtD
Ruxolitinib—Infestation NOS—Betaxolol—glaucoma	0.00148	0.00463	CcSEcCtD
Ruxolitinib—Nervous system disorder—Brimonidine—glaucoma	0.00147	0.00462	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Bimatoprost—glaucoma	0.00147	0.00459	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Brinzolamide—glaucoma	0.00146	0.00458	CcSEcCtD
Ruxolitinib—Skin disorder—Brimonidine—glaucoma	0.00146	0.00457	CcSEcCtD
Ruxolitinib—Dizziness—Latanoprost—glaucoma	0.00145	0.00454	CcSEcCtD
Ruxolitinib—Infection—Travoprost—glaucoma	0.00142	0.00445	CcSEcCtD
Ruxolitinib—Headache—Methazolamide—glaucoma	0.00142	0.00444	CcSEcCtD
Ruxolitinib—Infection—Brinzolamide—glaucoma	0.0014	0.00439	CcSEcCtD
Ruxolitinib—Nervous system disorder—Travoprost—glaucoma	0.0014	0.00439	CcSEcCtD
Ruxolitinib—Epistaxis—Betaxolol—glaucoma	0.0014	0.00437	CcSEcCtD
Ruxolitinib—Skin disorder—Travoprost—glaucoma	0.00139	0.00435	CcSEcCtD
Ruxolitinib—Nervous system disorder—Brinzolamide—glaucoma	0.00138	0.00434	CcSEcCtD
Ruxolitinib—Headache—Latanoprost—glaucoma	0.00137	0.0043	CcSEcCtD
Ruxolitinib—Skin disorder—Brinzolamide—glaucoma	0.00137	0.00429	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Acetazolamide—glaucoma	0.00135	0.00424	CcSEcCtD
Ruxolitinib—Fatigue—Acetazolamide—glaucoma	0.00135	0.00423	CcSEcCtD
Ruxolitinib—Infection—Pilocarpine—glaucoma	0.00135	0.00422	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Pilocarpine—glaucoma	0.00133	0.00416	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Brimonidine—glaucoma	0.0013	0.00407	CcSEcCtD
Ruxolitinib—Fatigue—Brimonidine—glaucoma	0.0013	0.00406	CcSEcCtD
Ruxolitinib—Asthenia—Apraclonidine—glaucoma	0.00126	0.00394	CcSEcCtD
Ruxolitinib—Pruritus—Apraclonidine—glaucoma	0.00124	0.00388	CcSEcCtD
Ruxolitinib—Body temperature increased—Acetazolamide—glaucoma	0.00124	0.00388	CcSEcCtD
Ruxolitinib—Fatigue—Dorzolamide—glaucoma	0.00124	0.00388	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Travoprost—glaucoma	0.00123	0.00387	CcSEcCtD
Ruxolitinib—Fatigue—Travoprost—glaucoma	0.00123	0.00386	CcSEcCtD
Ruxolitinib—Weight decreased—Timolol—glaucoma	0.00123	0.00384	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Brinzolamide—glaucoma	0.00122	0.00382	CcSEcCtD
Ruxolitinib—Asthenia—Bimatoprost—glaucoma	0.00122	0.00382	CcSEcCtD
Ruxolitinib—Fatigue—Brinzolamide—glaucoma	0.00122	0.00381	CcSEcCtD
Ruxolitinib—Pruritus—Bimatoprost—glaucoma	0.0012	0.00376	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Pilocarpine—glaucoma	0.00117	0.00367	CcSEcCtD
Ruxolitinib—Dizziness—Apraclonidine—glaucoma	0.00116	0.00363	CcSEcCtD
Ruxolitinib—Malnutrition—Betaxolol—glaucoma	0.00116	0.00362	CcSEcCtD
Ruxolitinib—Epistaxis—Timolol—glaucoma	0.00114	0.00357	CcSEcCtD
Ruxolitinib—Body temperature increased—Dorzolamide—glaucoma	0.00114	0.00356	CcSEcCtD
Ruxolitinib—Asthenia—Acetazolamide—glaucoma	0.00112	0.00352	CcSEcCtD
Ruxolitinib—Dizziness—Bimatoprost—glaucoma	0.00112	0.00352	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.00112	0.00352	CcSEcCtD
Ruxolitinib—Headache—Apraclonidine—glaucoma	0.0011	0.00344	CcSEcCtD
Ruxolitinib—Asthenia—Brimonidine—glaucoma	0.00108	0.00338	CcSEcCtD
Ruxolitinib—Infection—Clonidine—glaucoma	0.00108	0.00337	CcSEcCtD
Ruxolitinib—Body temperature increased—Pilocarpine—glaucoma	0.00107	0.00336	CcSEcCtD
Ruxolitinib—Anaemia—Betaxolol—glaucoma	0.00107	0.00335	CcSEcCtD
Ruxolitinib—Pruritus—Brimonidine—glaucoma	0.00106	0.00333	CcSEcCtD
Ruxolitinib—Headache—Bimatoprost—glaucoma	0.00106	0.00333	CcSEcCtD
Ruxolitinib—Nervous system disorder—Clonidine—glaucoma	0.00106	0.00333	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Clonidine—glaucoma	0.00106	0.00332	CcSEcCtD
Ruxolitinib—Skin disorder—Clonidine—glaucoma	0.00105	0.0033	CcSEcCtD
Ruxolitinib—Dizziness—Acetazolamide—glaucoma	0.00104	0.00324	CcSEcCtD
Ruxolitinib—Asthenia—Dorzolamide—glaucoma	0.00103	0.00323	CcSEcCtD
Ruxolitinib—Asthenia—Travoprost—glaucoma	0.00103	0.00321	CcSEcCtD
Ruxolitinib—Pruritus—Dorzolamide—glaucoma	0.00102	0.00318	CcSEcCtD
Ruxolitinib—Asthenia—Brinzolamide—glaucoma	0.00101	0.00317	CcSEcCtD
Ruxolitinib—Pruritus—Travoprost—glaucoma	0.00101	0.00317	CcSEcCtD
Ruxolitinib—Pruritus—Brinzolamide—glaucoma	0.000999	0.00313	CcSEcCtD
Ruxolitinib—Dizziness—Brimonidine—glaucoma	0.000994	0.00311	CcSEcCtD
Ruxolitinib—Headache—Acetazolamide—glaucoma	0.000981	0.00307	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000977	0.00306	CcSEcCtD
Ruxolitinib—Asthenia—Pilocarpine—glaucoma	0.000974	0.00305	CcSEcCtD
Ruxolitinib—Pruritus—Pilocarpine—glaucoma	0.00096	0.00301	CcSEcCtD
Ruxolitinib—Dizziness—Dorzolamide—glaucoma	0.00095	0.00297	CcSEcCtD
Ruxolitinib—Dizziness—Travoprost—glaucoma	0.000946	0.00296	CcSEcCtD
Ruxolitinib—Malnutrition—Timolol—glaucoma	0.000944	0.00296	CcSEcCtD
Ruxolitinib—Headache—Brimonidine—glaucoma	0.000942	0.00295	CcSEcCtD
Ruxolitinib—Infection—Betaxolol—glaucoma	0.000937	0.00294	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Clonidine—glaucoma	0.000936	0.00293	CcSEcCtD
Ruxolitinib—Fatigue—Clonidine—glaucoma	0.000934	0.00293	CcSEcCtD
Ruxolitinib—Dizziness—Brinzolamide—glaucoma	0.000934	0.00292	CcSEcCtD
Ruxolitinib—Nervous system disorder—Betaxolol—glaucoma	0.000925	0.0029	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Betaxolol—glaucoma	0.000924	0.00289	CcSEcCtD
Ruxolitinib—Skin disorder—Betaxolol—glaucoma	0.000916	0.00287	CcSEcCtD
Ruxolitinib—Headache—Dorzolamide—glaucoma	0.0009	0.00282	CcSEcCtD
Ruxolitinib—Dizziness—Pilocarpine—glaucoma	0.000897	0.00281	CcSEcCtD
Ruxolitinib—Headache—Travoprost—glaucoma	0.000896	0.00281	CcSEcCtD
Ruxolitinib—Headache—Brinzolamide—glaucoma	0.000884	0.00277	CcSEcCtD
Ruxolitinib—Body temperature increased—Clonidine—glaucoma	0.000857	0.00268	CcSEcCtD
Ruxolitinib—Headache—Pilocarpine—glaucoma	0.00085	0.00266	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Betaxolol—glaucoma	0.000814	0.00255	CcSEcCtD
Ruxolitinib—Fatigue—Betaxolol—glaucoma	0.000813	0.00255	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000798	0.0025	CcSEcCtD
Ruxolitinib—Asthenia—Clonidine—glaucoma	0.000777	0.00244	CcSEcCtD
Ruxolitinib—Pruritus—Clonidine—glaucoma	0.000767	0.0024	CcSEcCtD
Ruxolitinib—Infection—Timolol—glaucoma	0.000766	0.0024	CcSEcCtD
Ruxolitinib—Nervous system disorder—Timolol—glaucoma	0.000756	0.00237	CcSEcCtD
Ruxolitinib—Skin disorder—Timolol—glaucoma	0.000749	0.00234	CcSEcCtD
Ruxolitinib—Body temperature increased—Betaxolol—glaucoma	0.000746	0.00234	CcSEcCtD
Ruxolitinib—Dizziness—Clonidine—glaucoma	0.000717	0.00224	CcSEcCtD
Ruxolitinib—Headache—Clonidine—glaucoma	0.000679	0.00213	CcSEcCtD
Ruxolitinib—Asthenia—Betaxolol—glaucoma	0.000677	0.00212	CcSEcCtD
Ruxolitinib—Pruritus—Betaxolol—glaucoma	0.000667	0.00209	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Timolol—glaucoma	0.000665	0.00208	CcSEcCtD
Ruxolitinib—Fatigue—Timolol—glaucoma	0.000664	0.00208	CcSEcCtD
Ruxolitinib—Dizziness—Betaxolol—glaucoma	0.000624	0.00195	CcSEcCtD
Ruxolitinib—Body temperature increased—Timolol—glaucoma	0.000609	0.00191	CcSEcCtD
Ruxolitinib—Headache—Betaxolol—glaucoma	0.000591	0.00185	CcSEcCtD
Ruxolitinib—Asthenia—Timolol—glaucoma	0.000553	0.00173	CcSEcCtD
Ruxolitinib—Pruritus—Timolol—glaucoma	0.000545	0.00171	CcSEcCtD
Ruxolitinib—Dizziness—Timolol—glaucoma	0.00051	0.0016	CcSEcCtD
Ruxolitinib—Headache—Timolol—glaucoma	0.000483	0.00151	CcSEcCtD
Ruxolitinib—ROCK1—Signaling Pathways—NTRK2—glaucoma	4.12e-05	7.56e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—BAD—glaucoma	4.12e-05	7.55e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—C3—glaucoma	4.08e-05	7.49e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metapathway biotransformation—CYP1B1—glaucoma	4.07e-05	7.47e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—TP53—glaucoma	4.07e-05	7.47e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—CAV1—glaucoma	4.02e-05	7.37e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—VEGFA—glaucoma	3.99e-05	7.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RPTOR—glaucoma	3.98e-05	7.3e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—CDKN1B—glaucoma	3.98e-05	7.3e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NTRK1—glaucoma	3.97e-05	7.28e-05	CbGpPWpGaD
Ruxolitinib—PLK4—Cell Cycle—TP53—glaucoma	3.93e-05	7.21e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—VEGFA—glaucoma	3.92e-05	7.19e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—C3—glaucoma	3.92e-05	7.19e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—VEGFA—glaucoma	3.91e-05	7.17e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—BCL2L1—glaucoma	3.91e-05	7.17e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—NOS3—glaucoma	3.91e-05	7.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NCK2—glaucoma	3.85e-05	7.07e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—NGF—glaucoma	3.82e-05	7.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—FN1—glaucoma	3.82e-05	7.01e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EDN1—glaucoma	3.78e-05	6.92e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MTHFR—glaucoma	3.77e-05	6.91e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—BCL2L1—glaucoma	3.75e-05	6.88e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—CDKN1B—glaucoma	3.74e-05	6.86e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—MMP9—glaucoma	3.68e-05	6.76e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CDKN2B—glaucoma	3.66e-05	6.71e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—C3—glaucoma	3.64e-05	6.67e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CA5A—glaucoma	3.63e-05	6.66e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NARFL—glaucoma	3.63e-05	6.66e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—NOS3—glaucoma	3.62e-05	6.64e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NGFR—glaucoma	3.6e-05	6.59e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—BAD—glaucoma	3.54e-05	6.49e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NGFR—glaucoma	3.54e-05	6.49e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL1A—glaucoma	3.53e-05	6.48e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EDN1—glaucoma	3.51e-05	6.44e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—APOE—glaucoma	3.51e-05	6.43e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SMO—glaucoma	3.48e-05	6.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—MMP9—glaucoma	3.48e-05	6.38e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CAV1—glaucoma	3.48e-05	6.37e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—MMP9—glaucoma	3.46e-05	6.35e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—TP53—glaucoma	3.44e-05	6.3e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL1A—glaucoma	3.43e-05	6.29e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—TNF—glaucoma	3.42e-05	6.27e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NTRK1—glaucoma	3.42e-05	6.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—BAD—glaucoma	3.4e-05	6.24e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—CDKN1B—glaucoma	3.4e-05	6.23e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—APOE—glaucoma	3.38e-05	6.21e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—CDKN1B—glaucoma	3.38e-05	6.2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SMO—glaucoma	3.38e-05	6.2e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—TNF—glaucoma	3.36e-05	6.16e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NTRK1—glaucoma	3.36e-05	6.16e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CAV1—glaucoma	3.35e-05	6.15e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL1A—glaucoma	3.33e-05	6.1e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CDKN2B—glaucoma	3.32e-05	6.09e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—PTGS2—glaucoma	3.31e-05	6.07e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—VEGFA—glaucoma	3.31e-05	6.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—MMP2—glaucoma	3.31e-05	6.06e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Biological oxidations—GSTM1—glaucoma	3.3e-05	6.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—C3—glaucoma	3.3e-05	6.05e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SMO—glaucoma	3.28e-05	6.02e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—MMP9—glaucoma	3.28e-05	6.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HDAC9—glaucoma	3.28e-05	6.01e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—BAD—glaucoma	3.27e-05	6e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metapathway biotransformation—GSTM1—glaucoma	3.26e-05	5.97e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NGF—glaucoma	3.23e-05	5.92e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—CDKN1B—glaucoma	3.22e-05	5.9e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—FN1—glaucoma	3.19e-05	5.85e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NTRK2—glaucoma	3.19e-05	5.84e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—BAD—glaucoma	3.15e-05	5.78e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—EDN1—glaucoma	3.15e-05	5.78e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CDKN2B—glaucoma	3.15e-05	5.77e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—CDKN1B—glaucoma	3.14e-05	5.75e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—MMP9—glaucoma	3.13e-05	5.75e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—VEGFA—glaucoma	3.13e-05	5.73e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—CDKN1B—glaucoma	3.13e-05	5.73e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CDKN1B—glaucoma	3.11e-05	5.71e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—VEGFA—glaucoma	3.11e-05	5.7e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—C3—glaucoma	3.1e-05	5.69e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CDKN2B—glaucoma	3.1e-05	5.68e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NTRK2—glaucoma	3.09e-05	5.67e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—C3—glaucoma	3.07e-05	5.63e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CDKN1B—glaucoma	3.04e-05	5.57e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—NOS3—glaucoma	3.04e-05	5.57e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—CDKN1B—glaucoma	3.03e-05	5.56e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EDN1—glaucoma	3.02e-05	5.54e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—C3—glaucoma	3.01e-05	5.53e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NTRK2—glaucoma	3e-05	5.5e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—BCL2L1—glaucoma	2.97e-05	5.45e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EDN1—glaucoma	2.97e-05	5.45e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—TP53—glaucoma	2.96e-05	5.42e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—VEGFA—glaucoma	2.94e-05	5.4e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—C3—glaucoma	2.92e-05	5.36e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—CDKN1B—glaucoma	2.91e-05	5.34e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—BCL2L1—glaucoma	2.88e-05	5.29e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CDKN1B—glaucoma	2.87e-05	5.26e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EDN1—glaucoma	2.86e-05	5.25e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—APOE—glaucoma	2.86e-05	5.24e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CAV1—glaucoma	2.83e-05	5.19e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—VEGFA—glaucoma	2.81e-05	5.16e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—BCL2L1—glaucoma	2.8e-05	5.13e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MTHFR—glaucoma	2.78e-05	5.1e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NGF—glaucoma	2.78e-05	5.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—C3—glaucoma	2.75e-05	5.05e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NGFR—glaucoma	2.73e-05	5.01e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NGF—glaucoma	2.73e-05	5.01e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—FN1—glaucoma	2.69e-05	4.94e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—BAD—glaucoma	2.69e-05	4.94e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—BAD—glaucoma	2.66e-05	4.88e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NGFR—glaucoma	2.65e-05	4.87e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—C3—glaucoma	2.64e-05	4.84e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—NOS3—glaucoma	2.63e-05	4.82e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—BAD—glaucoma	2.61e-05	4.79e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL1A—glaucoma	2.6e-05	4.77e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NTRK1—glaucoma	2.6e-05	4.76e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—C3—glaucoma	2.6e-05	4.76e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—APOE—glaucoma	2.59e-05	4.75e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NGFR—glaucoma	2.57e-05	4.72e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CAV1—glaucoma	2.57e-05	4.71e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SMO—glaucoma	2.56e-05	4.7e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—BAD—glaucoma	2.54e-05	4.65e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—NOS3—glaucoma	2.54e-05	4.65e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—TNF—glaucoma	2.52e-05	4.63e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NTRK1—glaucoma	2.52e-05	4.63e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN2B—glaucoma	2.52e-05	4.61e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TP53—glaucoma	2.5e-05	4.58e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—C3—glaucoma	2.5e-05	4.58e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—MMP9—glaucoma	2.48e-05	4.56e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CDKN1B—glaucoma	2.47e-05	4.52e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—APOE—glaucoma	2.46e-05	4.51e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NTRK1—glaucoma	2.45e-05	4.49e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CAV1—glaucoma	2.43e-05	4.46e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—APOE—glaucoma	2.42e-05	4.43e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—BAD—glaucoma	2.41e-05	4.43e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PTGS2—glaucoma	2.4e-05	4.41e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CAV1—glaucoma	2.39e-05	4.39e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN2B—glaucoma	2.39e-05	4.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CDKN1B—glaucoma	2.37e-05	4.34e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TP53—glaucoma	2.35e-05	4.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NTRK2—glaucoma	2.34e-05	4.3e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN2B—glaucoma	2.32e-05	4.26e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—FN1—glaucoma	2.32e-05	4.25e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EDN1—glaucoma	2.3e-05	4.21e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—BAD—glaucoma	2.29e-05	4.2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—C3—glaucoma	2.28e-05	4.19e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—FN1—glaucoma	2.28e-05	4.18e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CDKN1B—glaucoma	2.28e-05	4.18e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN2B—glaucoma	2.25e-05	4.13e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—BAD—glaucoma	2.25e-05	4.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—VEGFA—glaucoma	2.23e-05	4.09e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EDN1—glaucoma	2.23e-05	4.09e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CDKN1B—glaucoma	2.2e-05	4.03e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—VEGFA—glaucoma	2.19e-05	4.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—BCL2L1—glaucoma	2.19e-05	4.01e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EDN1—glaucoma	2.16e-05	3.97e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NOS3—glaucoma	2.14e-05	3.92e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—glaucoma	2.13e-05	3.9e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NGF—glaucoma	2.11e-05	3.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MTHFR—glaucoma	2.11e-05	3.87e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NGF—glaucoma	2.05e-05	3.76e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MMP9—glaucoma	2.03e-05	3.73e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NGFR—glaucoma	2.01e-05	3.69e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—C3—glaucoma	2.01e-05	3.68e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NGF—glaucoma	1.99e-05	3.65e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—BAD—glaucoma	1.98e-05	3.63e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—APOE—glaucoma	1.96e-05	3.6e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—C3—glaucoma	1.95e-05	3.57e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CAV1—glaucoma	1.94e-05	3.57e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NOS3—glaucoma	1.94e-05	3.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TNF—glaucoma	1.91e-05	3.51e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NTRK1—glaucoma	1.91e-05	3.51e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—C3—glaucoma	1.89e-05	3.47e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CDKN1B—glaucoma	1.88e-05	3.44e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—APOE—glaucoma	1.87e-05	3.43e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CDKN1B—glaucoma	1.85e-05	3.4e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CAV1—glaucoma	1.85e-05	3.39e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NOS3—glaucoma	1.84e-05	3.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—BAD—glaucoma	1.83e-05	3.35e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—VEGFA—glaucoma	1.83e-05	3.35e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CDKN1B—glaucoma	1.82e-05	3.34e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—APOE—glaucoma	1.81e-05	3.33e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NOS3—glaucoma	1.81e-05	3.32e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CAV1—glaucoma	1.8e-05	3.3e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTGS2—glaucoma	1.77e-05	3.25e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CA1—glaucoma	1.77e-05	3.25e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CDKN1B—glaucoma	1.77e-05	3.24e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—FN1—glaucoma	1.76e-05	3.23e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN2B—glaucoma	1.76e-05	3.23e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—APOE—glaucoma	1.76e-05	3.23e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CAV1—glaucoma	1.74e-05	3.2e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—BAD—glaucoma	1.74e-05	3.19e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CTSA—glaucoma	1.72e-05	3.15e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MMP9—glaucoma	1.72e-05	3.15e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—FN1—glaucoma	1.71e-05	3.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EDN1—glaucoma	1.69e-05	3.1e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—BAD—glaucoma	1.69e-05	3.1e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CDKN1B—glaucoma	1.68e-05	3.08e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FN1—glaucoma	1.66e-05	3.04e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—glaucoma	1.65e-05	3.03e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—BAD—glaucoma	1.64e-05	3.01e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CA2—glaucoma	1.62e-05	2.98e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CDKN1B—glaucoma	1.59e-05	2.92e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CDKN1B—glaucoma	1.57e-05	2.88e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NGF—glaucoma	1.55e-05	2.85e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—VEGFA—glaucoma	1.54e-05	2.83e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MMP9—glaucoma	1.48e-05	2.71e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—C3—glaucoma	1.48e-05	2.71e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOS3—glaucoma	1.47e-05	2.7e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MMP9—glaucoma	1.45e-05	2.66e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NOS3—glaucoma	1.4e-05	2.57e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—glaucoma	1.38e-05	2.53e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDKN1B—glaucoma	1.38e-05	2.53e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOE—glaucoma	1.37e-05	2.52e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CAV1—glaucoma	1.36e-05	2.5e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NOS3—glaucoma	1.36e-05	2.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—glaucoma	1.35e-05	2.47e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—glaucoma	1.33e-05	2.43e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NOS3—glaucoma	1.32e-05	2.42e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—glaucoma	1.3e-05	2.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FN1—glaucoma	1.3e-05	2.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BAD—glaucoma	1.28e-05	2.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN1B—glaucoma	1.27e-05	2.34e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1B—glaucoma	1.21e-05	2.22e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1B—glaucoma	1.18e-05	2.16e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—glaucoma	1.16e-05	2.14e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TXN—glaucoma	1.14e-05	2.1e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1B—glaucoma	1.14e-05	2.09e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—glaucoma	1.12e-05	2.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—glaucoma	1.09e-05	2e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—glaucoma	1.06e-05	1.94e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOS3—glaucoma	1.03e-05	1.89e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—glaucoma	1.01e-05	1.85e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—glaucoma	1e-05	1.84e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—glaucoma	9.86e-06	1.81e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—glaucoma	9.79e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—glaucoma	9.5e-06	1.74e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1B—glaucoma	8.92e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTT1—glaucoma	8.87e-06	1.63e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—glaucoma	8.26e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—glaucoma	7.62e-06	1.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—glaucoma	7.42e-06	1.36e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—glaucoma	7.4e-06	1.36e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—glaucoma	7.17e-06	1.32e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP1B1—glaucoma	7.06e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCA1—glaucoma	7.06e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTM1—glaucoma	5.65e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—glaucoma	5.61e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTHFR—glaucoma	4.99e-06	9.15e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOE—glaucoma	4.65e-06	8.52e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CAV1—glaucoma	4.6e-06	8.44e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NOS3—glaucoma	3.48e-06	6.38e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—glaucoma	3.18e-06	5.84e-06	CbGpPWpGaD
